Qiang Li > DLA Piper > Shanghai, China > Lawyer Profile

DLA Piper
36/F SHANGHAI WORLD FINANCIAL CENTRE
100 CENTURY AVENUE, PUDONG
SHANGHAI 200120
China

Lawyer Rankings

China > Corporate and M&A: foreign firms

(Leading individuals)

Qiang Li – DLA Piper

Active across sectors including insurance, life sciences, semiconductors, automobiles and logistics, DLA Piper advises on an equally broad range of transactions, acting on mandates for acquisitions, disposals, mergers and investments. The team is particularly noted for its work with investment funds, including private equity houses, where its clients include Chinese private and state-owned funds as well as international sponsors. The group is jointly led from Shanghai by Roy Chan, a specialist in the insurance and financial services sectors, and Qiang Li, who handles both strategic M&A and private equity transactions. Stewart Wang and Beijing-based James Chang are also key figures in the practice with substantial experience in cross-border M&A.

China > Life sciences and healthcare: foreign firms

Acting for both foreign multinational corporations and China-based clients, DLA Piper‘s active and sizeable Greater China team fields specialists in corporate law, IP, regulatory and compliance, investigations, capital markets, employment and tax. The China life sciences practice is co-led by Hong Kong-based compliance and investigations specialist, Sammy Fang; and recently promoted partner Ting Xiao in Shanghai, who focuses on life sciences-related regulatory and IP work. Also on the mainland, Qiang Li‘s broad corporate practice includes advising Chinese life science companies, while Christine Liu in Hong Kong represents pharmaceutical and medical device companies in internal investigations.

China > Private equity: foreign firms

Delivering ‘great technical excellence and business acumen with real- world solutions‘, DLA Piper‘s Greater China private equity practice advises on the legal and commercial issues that arise at all stages of the private equity life cycle (both within and out of China). The group acts for high-profile private equity funds, established investment firms, and family offices and other equity financial investors, on buyouts, M&A, cross-border transactions, joint ventures, and control and minority investments. Other key areas range from venture and growth capital, to distressed investments, fund formation and limited partner investments. In Shanghai, the recent track record of ‘practicalStewart Wang and Qiang Li includes advising Wise Road Capital on its $1.46bn acquisition of Taiwanese semiconductor giant, ASE Technology Co. Over in Beijing, James Chang is a transactional and regulatory specialist, while Hong Kong-based Luke Gannon is the firm’s highly regarded Asia corporate head.